Seres Therapeutics, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company focused on developing microbiome therapeutics to treat medically important diseases through the restoration, stabilization, and enhancement of the human microbiome. The company develops and commercializes investigational oral live biotherapeutic products, including VOWST (fecal microbiota spores, live-brpk), an FDA-approved therapy for the prevention of Clostridioides difficile (C. diff) infection recurrence in adults following antibiotic treatment; SER-109, an oral capsule formulation of Firmicutes spores for the same indication; SER-155, an oral live biotherapeutic targeting enteric pathogens for patients undergoing allogeneic hematopoietic stem cell transplantation; and SER-155CT, a variant designed to reduce infection risk and graft-versus-host disease in similar patients, along with earlier-stage candidates like SER-344 for inflammatory bowel disease and SER-382 for food allergy. Seres operates primarily in the United States, with research and development activities centered on its Cambridge, Massachusetts headquarters, where the company was founded in 2010. In recent developments within the last two years, Seres completed the commercial launch of VOWST in 2023 following FDA approval, entered into a strategic collaboration with Nestlé Health Science to co-promote VOWST and expand commercialization efforts, reported positive Phase 3 data for SER-109 leading to supplemental Biologics License Application submission, and advanced SER-155 into clinical studies amid ongoing funding through equity offerings and partnerships to support its pipeline expansion in infectious diseases and immunotherapy.
Company News
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
Seres Therapeutics (NASDAQ:MCRB) Share Price Breaks Below 50 Day Moving Average – Should You Sell?
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Seres Therapeutics Posts Early Data for Cancer Therapy Complication
Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis Transcript
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics to Present at CARB-X Investor Day